Tazemetostat Yields Promising Results in Patients With Follicular Lymphoma
Tazemetostat yielded clinically meaningful, durable responses and was well tolerated in patients with relapsed or refractory follicular lymphoma.
Hematologic Cancers
Unfitness Criteria Predict Early Mortality After Intensive Chemotherapy in Acute Myeloid Leukemia
The Ferrara criteria are widely used to identify patients with AML who are most suitable for intensive chemotherapy, though the accuracy is unknown.
Machine Learning Helped Predict Short-Term Cancer Mortality
Use of the algorithm could lead to improved use of supportive care.
FDA Grants Full Approval to Venclexta for Acute Myeloid Leukemia
The full approval was based on efficacy and safety data from the phase 3 VIALE-A (M15-656) and VIALE-C (M16-043) studies.
British Society for Haematology Guideline Update for the Diagnosis and Management of Chronic Myeloid Leukemia
The British Society for Haematology has published updated guidelines for the diagnosis and management of chronic myeloid leukemia in adults and children.
Geriatric Assessment Instruments Underutilized Among Community Oncologists, Hematologists
Research presented at ASCO Quality Care Symposium revealed a need for better education regarding geriatric assessment tools among oncology clinicians.
Promising, Early Results for Combined HDAC and mTOR Inhibition in Relapsed/Refractory Hodgkin Lymphoma
Responses were also observed in patients previously treated with HDAC or mTOR inhibitors.
Modern Radiation Therapy Limits Radiation Doses to Organs at Risk in Hodgkin Lymphoma
Combined modality therapy for early-stage favorable HL yielded excellent outcomes and limited excess radiation doses to organs at risk.
Brentuximab Vedotin Plus Nivolumab as Chemotherapy-Free Strategy for Hodgkin Lymphoma in Older Patients
Findings suggest that brentuximab vedotin plus nivolumab was well tolerated and active in older patients with previously untreated HL with comorbidities.
Underrepresentation of Women in Clinical Trials Persists
Clinical trials leading to US FDA approvals of anticancer therapies continue to underrepresent women.
-
Loading...
-
Loading...
Next post in General Hematology
